Key Takeaways
- Solid quarter, confident outlook: Revenue grew 7.4% YoY driven by Americas and EAP, while Beauty & Cosmetics surged over 20%. Management is confident of delivering double-digit growth in FY26.
- Beauty & Cosmetics is the growth engine: Over 20% growth this quarter, fueled by capability investments and sharper execution, with a clear strategy to chase smaller customers and a healthy order pipeline.
- Margins expanded without stretching: EBITDA margin reached 20.3% for the full year, a 169 bps expansion, with India showing a sharp 170 bps sequential recovery. Management sees further room in Americas and Europe.
- Tariffs are a net opportunity, not a threat: With local US manufacturing and contractual pass-throughs, management views the new tariff environment as a potential source of competitive advantage.
- What to watch next quarter: The pace of Beauty & Cosmetics acceleration, the ramp-up of the new Brazil capacity, and any early signs of a macro recovery that could unlock the double-digit growth ambition.
The Beauty & Cosmetics Pivot
- Over 20% growth this quarter, accelerating quarter-on-quarter, driven by focused investments in Neo Seam tubes, superior printing, and deeper customer engagement. The order pipeline remains healthy with new customer wins across geographies.
- "No order too small" strategy: The company has hired more salespeople ("hunters") to acquire smaller B&C customers and has completed backend flexibility investments across plants to handle larger tube types, smaller MOQs, and more dias.
- Selective extruded tube push: Making targeted investments in extruded tubes to complement the core laminated tube offering, including in China where extruded capability is being built out.
- Brazil sold out, expanding now: Existing B&C capacity in Brazil is fully utilized; a new expansion is expected to be operational this quarter itself, removing a near-term bottleneck.
- The blended math: If B&C sustains mid-to-high teens growth globally, and Oral Care sees some recovery, the blended company growth enters double-digit territory. B&C's higher ASP also provides better fixed-cost leverage over time.
Kripalu: "On Beauty & Cosmetics, the mantra in the company is we will do what it takes to accelerate Beauty & Cosmetics. No size of order is too small for EPL to go and service that order."
Margin Trajectory & Levers
- Full-year margin expansion of 169 bps to 20.3% EBITDA was achieved without stretching the P&L, per management. Raw materials have been benign and range-bound, with contractual pass-throughs insulating the business from commodity swings.
- India recovery is underway: India margins improved 100 bps YoY and 170 bps sequentially, driven by operational efficiencies and an improved product mix. Management acknowledges further corrections are still needed in India.
- Regional upside remains: Americas (18-19%) and Europe (16-17%) are in the right range but still have margin improvement opportunities. EAP's sharp sequential EBIT drop is a seasonal Chinese New Year effect plus technology tax benefit fluctuations; full-year comparison is the right lens.
- Cost leadership as a moat: Management claims to be the lowest-cost producer globally by at least 3%, attributing it to an Indian frugality culture and the ability to extract more from machines and run them longer than any competitor.
- Commitment to margin growth ahead of revenue: Management is confident of delivering EBITDA growth ahead of revenue growth, with sharp focus on CAPEX and interest costs positioning the company for continued PAT growth and ROCE improvement.
Kripalu: "As a principal I can tell you we are the lowest cost producer in the world right by at least 3%, if not more. And that is because compared to any other regional competitor, the Indian mindset of frugality as a culture, right, and our ability to extract more from the machines and run our machines for longer than anybody else in the world."
Geographic Performance & Expansion
| Region | Trend | Commentary |
|---|---|---|
| Americas | ▲ Solid growth | Revenue growth driver alongside EAP; margins at 18-19% with room to improve. Local US manufacturing insulates against tariffs. |
| EAP | ▲ Strong growth | Grew 9% YoY in Q4 despite Chinese New Year headwinds; will get a further boost in H2 as Thailand comes on stream. EAP must perform for the global double-digit ambition. |
| Europe | ▬ Modest growth | Margins at 16-17% are in the right range with some opportunity left; the Poland plant turnaround has helped the regional profit mix. |
| AMESA (India) | ▬ Flat overall | Underlying tube demand remains positive; flatness was partly due to lower intercompany laminate sales, a quarterly inventory variation, not structural. Tube revenue growth ex-laminates is mid-to-high single digit. |
- Thailand greenfield is progressing as planned and will contribute from H2 onwards. It starts small but aims to scale fast, with a large part of expenses hitting in FY26.
- Brazil capacity expansion for Beauty & Cosmetics is expected to be operational this quarter, relieving a sold-out position.
- India export aggression: The company is mounting more aggression on exports to the Middle East and Africa from its India base.
Tariffs & Competitive Dynamics
- Minimal direct impact expected: EPL has local manufacturing in the US, exports to the US are relatively small, and the company has contractual pass-through of duties with most customers.
- Potential competitive advantage: Management sees the tariff environment as a possible net positive, as regional competitors without local US manufacturing or diversified supply chains face greater disruption.
- China-to-US exposure exists but is manageable: A "material percentage" in double-digits of US tubes are exported from China, but management declined to specify the exact figure. The contractual pass-through mechanism covers these flows.
Kripalu: "Actually, there could be a source of competitive advantage, right as this thing plays out."
Capital Allocation & Returns
- FY26 CAPEX set at ₹380-390 crore, sufficient to cover growth plans and the Thailand greenfield.
- Dividend increased: Final dividend proposed at ₹2.50 per share, taking the full-year dividend to ₹5 per share, up from ₹4.35 last year. Management commits to continuing a strong payout policy with marginal improvement year-over-year.
- M&A appetite is open: The company is "very open to M&A" and actively looking for opportunities, even while deleveraging and maintaining the dividend. Further greenfield expansion will also be explored as opportunities arise.
- ROCE trajectory: Short term, ROCE should "definitely cross 20"; long term, it can expand even faster as margins improve and capital efficiency increases.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | Double-digit growth globally | FY26 |
| EBITDA growth | EBITDA growth ahead of revenue growth | FY26 |
| Beauty & Cosmetics growth | Mid-to-high teens growth globally | FY26 |
| Brazil capacity | New B&C capacity operational | Q1 FY26 (this quarter) |
| Thailand greenfield | Begin contributing to revenue | H2 FY26 |
| CAPEX | ₹380-₹390 crore spend | FY26 |
| ROCE | Cross 20% | Short term |
| Dividend | Continue strong payout with marginal YoY improvement | Ongoing |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue growth | 7.4% YoY |
| EBITDA growth | 17.7% YoY |
| PAT growth | 42.4% YoY |
| EBITDA margin | 20.3%, 11th consecutive quarter of expansion |
| Full-year revenue growth | 7.6% YoY |
| Full-year EBITDA growth | 17.5% YoY, margin expansion of 169 bps |
| Full-year underlying PAT growth | 44.6% YoY |
| EPS | ₹11.38 in FY25, up 44% from ₹7.88 in FY24 |
| ROCE | 18%, expanded by 335 bps |
| Net debt to EBITDA | 0.54x |
| Personal Care & Beyond revenue share | 48% of total business |
| Personal Care & Beyond growth | 10.3% YoY (full year) |
| Oral Care growth | 5.6% YoY (full year) |
| Beauty & Cosmetics growth | Over 20% YoY |
| India margin improvement | 100 bps YoY, 170 bps sequential |
| EAP region growth | 9% YoY |
| Europe EBITDA margin | 16%–17% |
| Americas EBITDA margin | 18%–19% |
| Recyclable portfolio share | 33%, up from 21% last year |
| Brazil capacity addition | ~4 crore tubes per year |
| FY26 CAPEX guidance | ₹380–₹390 crore |
| FY25 dividend per share | ₹5.00 (proposed final of ₹2.50 included), vs ₹4.35 last year |
| Steady-state tax rate guidance | 18%–22% |